Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806208 | 0.87 | DRD2 (0.51) | HTR1AMAOBDRD2DRD3HTR7 | |
| SCHEMBL6784528 | 0.84 | HTR1A (0.51) | HTR1AMAOBDRD2DRD3HTR7 | |
| SCHEMBL6790045 | 0.79 | DRD4 (0.49) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL6811157 | 0.79 | DRD2 (0.45) | HTR1AMAOBDRD2DRD3HTR7 | |
| SCHEMBL6710692 | 0.79 | DRD2 (0.49) | HTR1AMAOBDRD2DRD3HTR7 | |
| SCHEMBL6709174 | 0.78 | DRD2 (0.61) | HTR1AMAOBDRD2DRD3HTR7 | |
| SCHEMBL6790041 | 0.77 | DRD4 (0.59) | DRD2DRD3 | |
| SCHEMBL6811161 | 0.77 | MAOB (0.42) | HTR1AMAOBDRD2DRD3HTR7 | |
| SCHEMBL6709241 | 0.77 | HTR1A (0.62) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL6709301 | 0.77 | MAOB (0.52) | HTR1AMAOBDRD2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | HTR1A 256/4885MAOB 2742/4885DRD2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.